UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Compare rebalancing frequency between index funds and target-date funds and what that means for risk, fees, and long-term performance. A quick look at when to expect adjustments.
28,361 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
When a tech giant faces a costly lawsuit over a celebrity image, it isn’t just a legal story—it’s a personal finance ...
A celebrity’s plea highlights a bigger money issue: how newborn SMA screening decisions touch family budgets. This gu...
Investors have been watching does planet labs stock slide for months. This guide breaks down the drivers, the risks, ...
A Sioux Falls crypto investor faces 29 federal counts in a scheme prosecutors say used eight entities and new investo...
Two popular dividend ETFs take different paths: one prioritizes growing income with minimal fees, the other aims for ...
After years of outsized gains, the magnificent seven faces a pullback. This guide explains how to evaluate the dip, p...
In 2026, the best real estate deals go to those who are proactive, data-driven, and connected. This guide shows rooki...
Silver miners surged 124% over the past year and platinum climbed 89%, but volatility has risen. Investors face a cle...
DVY’s 3.3% yield looks weak when set against a 4.55% 10-year Treasury, underscoring a shifting landscape for income-f...
Winter weather and growing data-center energy use push electricity bills higher than inflation, placing new pressure ...
AI optimism pushed valuations to lofty highs. This guide explains why stocks wall street says to be cautious about tw...